FULL CHAPTER 61
問題一覧
1
Biologic
2
Interpersonal
3
Concentrate on the patient and not think of re- sponses to the patient while he or she is speaking.
4
Clarifying
5
Thought content
6
"Do you have any thoughts of harming yourself?"
7
Anxiety disorder
8
Mild anxiety
9
Guide the patient in relaxation techniques to dis- tract him when flashbacks occur.
10
"OK. I am going that way myself."
11
Effexor and Ativan
12
Schizophrenia
13
Antiparkinsonian
14
Tardive dyskinesia
15
Traumatic event in childhood
16
Orthostatic hypotension
17
Offer nutritious finger foods and high-protein milk shakes to eat on the go.
18
Manic episode
19
Decrease the stimuli and use restraints if all other measures fail.
20
Maintain hydration.
21
Borderline
22
Obsessive-compulsive
23
Neoplasms
24
Diminished awareness of surroundings, Derealization, Depersonalization, Amnesia
25
A car backfiring being perceived as gunfire, The television news being perceived as someone talking to you, A spot on the wall being perceived as a spider
26
sensorium
27
1 month
28
Oxazepam (Serax)
29
Fluvoxamine (Luvox)
30
Patient reports sleeping better and increased in- terest in activities.
31
It requires medical intervention to treat.
32
Discuss, review, and validate the behavior moni- toring system and intervention flow sheet the patient and significant other will continue to use following
33
Risk of injury when using machinery
34
Patient with recent anxiety reactions
35
"You may feel dizzy or unsteady when rising to a standing position."
36
There is minimal potential for abuse.
37
provide for patient safety.
38
intramuscularly.
39
She is able to sleep 5 hours during the night., The tremor and pacing she exhibited on admission are reduced., She is able to attend and actively participate in group sessions.
40
Alcohol, Antihistamines, Analgesics, Sedatives, Hypnotics
41
Reduced need for sedation and analgesia before and after surgery, Control of itching in allergic reactions, Control of vomiting
42
Physical examination, Psychological evaluation, History of precipitation stressors, Medication history, Substance abuse history
43
readily cross into breast milk, enter fetal circulation
44
Distinct episodes of elation
45
Morphine
46
They do not cause the anticholinergic and cardio- vascular adverse effects.
47
Bipolar disorders
48
Social withdrawal
49
Patient age and gender
50
1 week
51
Blocking their destruction
52
Neck stiffness
53
Drowsiness
54
Bradycardia
55
"If I have the urge to smoke, I will take more med- ication."
56
Assess the patient for thoughts of suicide.
57
in 14 days following the last dose of
58
fluid volume deficit.
59
Current medications and medical history, Recent stressors and support system, Family history of mood disorder, Dietary patterns
60
"Persistent vomiting and profuse diarrhea are signs of toxicity and must be reported to the healthcare provider immediately.", "It is important to comply with schedules for blood tests to assess therapeutic levels.", The common adverse effects to expect, which are excessive nausea, anorexia, and abdominal cramps, tend to resolve.", "Take the medication with food or milk."
61
Dryness of the mouth is normal; sucking on sugar free hard candy and ice chips or chewing gum may help alleviate this problem., Rise slowly from a supine or sitting posi- tion to avoid dizziness and orthostatic hypotension., Avoid alcohol and barbiturates.
62
Beer, Aged cheeses, Bananas
63
Compliance with medication therapy within the last 2 months, Nonverbal interactions among patient and significant others present, Evaluation of the coherency, relevancy, and organization of thoughts in responses, Appearance and posture
64
SSRIs inhibit the destruction and reuptake of serotonin at the synaptic cleft., Monocyclic antidepressants such as bupropion (Wellbutrin) have an unknown mechanism of action., SNRIs prolong the action of neurotransmitters by decreasing the destruction of serotonin and norepinephrine.
65
Tranylcypromine (Parnate) Willihnganz, Lithium (Eskalith), Warfarin (Coumadin), Propranolol (Inderal)
66
Dryness of mouth, nose, and throat, Constipation, Urinary retention, Blurred vision
67
Hold the MAOI drug., Consult with the prescribing healthcare provider.
68
Hallucinations
69
Administration of depot antipsychotic medication
70
Extrapyramidal effects
71
Dystonic reactions
72
Agranulocytosis
73
Firmly redirect the patient to take the medication.
74
Painful dystonic reactions can occur in the first 72 hours of initiation of therapy.
75
Milligram doses used for the medication
76
Extrapyramidal symptoms
77
Measure the patient's waist circumference.
78
diphenhydramine
79
Deterioration of social functioning, Reporting that the FBI has solicited important secret information from his phone conversations, Confirmation of hearing voices in his head, Changing the topic of conversation inappropriately
80
Benzodiazepines allow for lower dosages of antipsychotic agents to be used, thereby decreasing serious adverse effects seen with high-dose therapy., It assists in calming the psy- chotic patient.
81
Spasmodic movements of muscle groups, Mask-like expression
82
Fever, Hypertension, Severe extrapyramidal symptoms, Alterations in consciousness
83
Be open and direct when handling the patient., Provide high-protein, high-calorie foods
84
Tardive dyskinesia, Neuroleptic malignant syndrome, Akathisia, Acute dystonia
85
Rapid increase in dosages will increase the frequency of adverse effects., Tardive dyskinesia may be re- versible in early stages, Full therapeutic response may require 6 to 8 weeks to be achieved.
86
Gingival hyperplasia
87
Hyperglycemia
88
Administer without mixing with other medications.
89
Trigeminal neuralgia pain
90
Valproic acid (Depakene)
91
Advise the patient that this adverse effect usually resolves but should be reported to the healthcare provider.
92
Topiramate (Topamax)
93
Nystagmus
94
Nystagmus
95
Nausea, vomiting, and indigestion are common during the initiation of therapy.
96
30 mg/min
97
"If I develop enlarged gums, I will stop taking the medication."
98
Determine patient's ancestry.
99
carbohydrates.
100
Placing padding around or under the patient's head, Positioning the patient on the side once the relaxation stage is entered to allow oral secretions to drain, Requesting additional assistance and/or necessary equipment in case the patient does not begin breathing spontaneously when the seizure is over
study
study
ユーザ名非公開 · 61問 · 1年前study
study
61問 • 1年前39
39
ユーザ名非公開 · 28問 · 1年前39
39
28問 • 1年前pretest
pretest
ユーザ名非公開 · 10問 · 1年前pretest
pretest
10問 • 1年前Chapter 1. History of Pharmacology
Chapter 1. History of Pharmacology
ユーザ名非公開 · 10問 · 1年前Chapter 1. History of Pharmacology
Chapter 1. History of Pharmacology
10問 • 1年前Chapter 2. Basics of Pharmacology
Chapter 2. Basics of Pharmacology
ユーザ名非公開 · 15問 · 1年前Chapter 2. Basics of Pharmacology
Chapter 2. Basics of Pharmacology
15問 • 1年前Chapter 3
Chapter 3
ユーザ名非公開 · 11問 · 1年前Chapter 3
Chapter 3
11問 • 1年前Chapter 4
Chapter 4
ユーザ名非公開 · 10問 · 1年前Chapter 4
Chapter 4
10問 • 1年前Chapter 5
Chapter 5
ユーザ名非公開 · 10問 · 1年前Chapter 5
Chapter 5
10問 • 1年前Chapter 9
Chapter 9
ユーザ名非公開 · 13問 · 1年前Chapter 9
Chapter 9
13問 • 1年前Chapter 10
Chapter 10
ユーザ名非公開 · 9問 · 1年前Chapter 10
Chapter 10
9問 • 1年前Chapter 11
Chapter 11
ユーザ名非公開 · 72問 · 1年前Chapter 11
Chapter 11
72問 • 1年前Chapter 12
Chapter 12
ユーザ名非公開 · 32問 · 1年前Chapter 12
Chapter 12
32問 • 1年前Chapter 15
Chapter 15
ユーザ名非公開 · 32問 · 1年前Chapter 15
Chapter 15
32問 • 1年前Chapter 13
Chapter 13
ユーザ名非公開 · 25問 · 1年前Chapter 13
Chapter 13
25問 • 1年前Chapter 62
Chapter 62
ユーザ名非公開 · 45問 · 1年前Chapter 62
Chapter 62
45問 • 1年前Immune System Disorder
Immune System Disorder
ユーザ名非公開 · 10問 · 1年前Immune System Disorder
Immune System Disorder
10問 • 1年前Chapter 8 Pain
Chapter 8 Pain
ユーザ名非公開 · 62問 · 1年前Chapter 8 Pain
Chapter 8 Pain
62問 • 1年前Endocrine VID
Endocrine VID
ユーザ名非公開 · 43問 · 1年前Endocrine VID
Endocrine VID
43問 • 1年前Chapter 49
Chapter 49
ユーザ名非公開 · 58問 · 1年前Chapter 49
Chapter 49
58問 • 1年前Chapter 49 PT2
Chapter 49 PT2
ユーザ名非公開 · 54問 · 1年前Chapter 49 PT2
Chapter 49 PT2
54問 • 1年前22
22
ユーザ名非公開 · 22問 · 1年前22
22
22問 • 1年前Chapter 50
Chapter 50
ユーザ名非公開 · 43問 · 1年前Chapter 50
Chapter 50
43問 • 1年前Chapter 50 PT 2
Chapter 50 PT 2
ユーザ名非公開 · 50問 · 1年前Chapter 50 PT 2
Chapter 50 PT 2
50問 • 1年前Chapter 50 PT 3
Chapter 50 PT 3
ユーザ名非公開 · 41問 · 1年前Chapter 50 PT 3
Chapter 50 PT 3
41問 • 1年前Chapter 50 PT 4
Chapter 50 PT 4
ユーザ名非公開 · 29問 · 1年前Chapter 50 PT 4
Chapter 50 PT 4
29問 • 1年前Chapter 34: Hypertension
Chapter 34: Hypertension
ユーザ名非公開 · 45問 · 1年前Chapter 34: Hypertension
Chapter 34: Hypertension
45問 • 1年前Chapter 34: Hypertension PT2
Chapter 34: Hypertension PT2
ユーザ名非公開 · 50問 · 1年前Chapter 34: Hypertension PT2
Chapter 34: Hypertension PT2
50問 • 1年前Chapter 34: Hypertension PT3
Chapter 34: Hypertension PT3
ユーザ名非公開 · 38問 · 1年前Chapter 34: Hypertension PT3
Chapter 34: Hypertension PT3
38問 • 1年前Chapter 34: Hypertension PT4
Chapter 34: Hypertension PT4
ユーザ名非公開 · 45問 · 1年前Chapter 34: Hypertension PT4
Chapter 34: Hypertension PT4
45問 • 1年前Chapter 34: Hypertension PT5
Chapter 34: Hypertension PT5
ユーザ名非公開 · 50問 · 1年前Chapter 34: Hypertension PT5
Chapter 34: Hypertension PT5
50問 • 1年前Chapter 33
Chapter 33
ユーザ名非公開 · 49問 · 1年前Chapter 33
Chapter 33
49問 • 1年前Chapter 35: Cardiac Disorders
Chapter 35: Cardiac Disorders
ユーザ名非公開 · 10問 · 1年前Chapter 35: Cardiac Disorders
Chapter 35: Cardiac Disorders
10問 • 1年前Chapter 33: Cardiovascular System Introduction Chapter 35: Cardiac Disorders
Chapter 33: Cardiovascular System Introduction Chapter 35: Cardiac Disorders
ユーザ名非公開 · 50問 · 1年前Chapter 33: Cardiovascular System Introduction Chapter 35: Cardiac Disorders
Chapter 33: Cardiovascular System Introduction Chapter 35: Cardiac Disorders
50問 • 1年前PT 2
PT 2
ユーザ名非公開 · 50問 · 1年前PT 2
PT 2
50問 • 1年前PT 3
PT 3
ユーザ名非公開 · 55問 · 1年前PT 3
PT 3
55問 • 1年前PT 4
PT 4
ユーザ名非公開 · 53問 · 1年前PT 4
PT 4
53問 • 1年前PT 5
PT 5
ユーザ名非公開 · 49問 · 1年前PT 5
PT 5
49問 • 1年前Chapter 36
Chapter 36
ユーザ名非公開 · 14問 · 1年前Chapter 36
Chapter 36
14問 • 1年前Vascular Disorders
Vascular Disorders
ユーザ名非公開 · 55問 · 1年前Vascular Disorders
Vascular Disorders
55問 • 1年前PT 2
PT 2
ユーザ名非公開 · 55問 · 1年前PT 2
PT 2
55問 • 1年前PT 3
PT 3
ユーザ名非公開 · 39問 · 1年前PT 3
PT 3
39問 • 1年前Chapter 43 Musculoskeletal System Introduction
Chapter 43 Musculoskeletal System Introduction
ユーザ名非公開 · 10問 · 1年前Chapter 43 Musculoskeletal System Introduction
Chapter 43 Musculoskeletal System Introduction
10問 • 1年前Chapter 44: Connective Tissue Disorders
Chapter 44: Connective Tissue Disorders
ユーザ名非公開 · 26問 · 1年前Chapter 44: Connective Tissue Disorders
Chapter 44: Connective Tissue Disorders
26問 • 1年前PT 2
PT 2
ユーザ名非公開 · 49問 · 1年前PT 2
PT 2
49問 • 1年前PT 3
PT 3
ユーザ名非公開 · 49問 · 1年前PT 3
PT 3
49問 • 1年前PT 4
PT 4
ユーザ名非公開 · 55問 · 1年前PT 4
PT 4
55問 • 1年前PT 5
PT 5
ユーザ名非公開 · 36問 · 1年前PT 5
PT 5
36問 • 1年前Chapter 45: Fractures
Chapter 45: Fractures
ユーザ名非公開 · 29問 · 1年前Chapter 45: Fractures
Chapter 45: Fractures
29問 • 1年前Chapter 46: Amputations
Chapter 46: Amputations
ユーザ名非公開 · 31問 · 1年前Chapter 46: Amputations
Chapter 46: Amputations
31問 • 1年前Chapter 45: Fractures Chapter 46: Amputations
Chapter 45: Fractures Chapter 46: Amputations
ユーザ名非公開 · 40問 · 1年前Chapter 45: Fractures Chapter 46: Amputations
Chapter 45: Fractures Chapter 46: Amputations
40問 • 1年前PT 2
PT 2
ユーザ名非公開 · 45問 · 1年前PT 2
PT 2
45問 • 1年前PT 3
PT 3
ユーザ名非公開 · 40問 · 1年前PT 3
PT 3
40問 • 1年前PT 4
PT 4
ユーザ名非公開 · 45問 · 1年前PT 4
PT 4
45問 • 1年前Chapter 56
Chapter 56
ユーザ名非公開 · 27問 · 1年前Chapter 56
Chapter 56
27問 • 1年前Chapter 57: Skin Disorders
Chapter 57: Skin Disorders
ユーザ名非公開 · 18問 · 1年前Chapter 57: Skin Disorders
Chapter 57: Skin Disorders
18問 • 1年前Chapter 56: New Integumentary System Introduction Chapter 57: Skin Disorders
Chapter 56: New Integumentary System Introduction Chapter 57: Skin Disorders
ユーザ名非公開 · 40問 · 1年前Chapter 56: New Integumentary System Introduction Chapter 57: Skin Disorders
Chapter 56: New Integumentary System Introduction Chapter 57: Skin Disorders
40問 • 1年前PT 2
PT 2
ユーザ名非公開 · 50問 · 1年前PT 2
PT 2
50問 • 1年前PT 3
PT 3
ユーザ名非公開 · 50問 · 1年前PT 3
PT 3
50問 • 1年前PT 4
PT 4
ユーザ名非公開 · 50問 · 1年前PT 4
PT 4
50問 • 1年前Chapter 25: Respiratory System Introduction
Chapter 25: Respiratory System Introduction
ユーザ名非公開 · 37問 · 1年前Chapter 25: Respiratory System Introduction
Chapter 25: Respiratory System Introduction
37問 • 1年前Chapter 26: Upper Respiratory Disorders
Chapter 26: Upper Respiratory Disorders
ユーザ名非公開 · 14問 · 1年前Chapter 26: Upper Respiratory Disorders
Chapter 26: Upper Respiratory Disorders
14問 • 1年前Chapter 27: Acute Lower Respiratory Disorders
Chapter 27: Acute Lower Respiratory Disorders
ユーザ名非公開 · 17問 · 1年前Chapter 27: Acute Lower Respiratory Disorders
Chapter 27: Acute Lower Respiratory Disorders
17問 • 1年前Chapter 27: Acute Lower Respiratory Disorders 1
Chapter 27: Acute Lower Respiratory Disorders 1
ユーザ名非公開 · 50問 · 1年前Chapter 27: Acute Lower Respiratory Disorders 1
Chapter 27: Acute Lower Respiratory Disorders 1
50問 • 1年前PT 2
PT 2
ユーザ名非公開 · 45問 · 1年前PT 2
PT 2
45問 • 1年前PT 3
PT 3
ユーザ名非公開 · 45問 · 1年前PT 3
PT 3
45問 • 1年前PT 4
PT 4
ユーザ名非公開 · 45問 · 1年前PT 4
PT 4
45問 • 1年前PT 5
PT 5
ユーザ名非公開 · 50問 · 1年前PT 5
PT 5
50問 • 1年前PT 6
PT 6
ユーザ名非公開 · 18問 · 1年前PT 6
PT 6
18問 • 1年前Chapter 07
Chapter 07
ユーザ名非公開 · 8問 · 12ヶ月前Chapter 07
Chapter 07
8問 • 12ヶ月前問題一覧
1
Biologic
2
Interpersonal
3
Concentrate on the patient and not think of re- sponses to the patient while he or she is speaking.
4
Clarifying
5
Thought content
6
"Do you have any thoughts of harming yourself?"
7
Anxiety disorder
8
Mild anxiety
9
Guide the patient in relaxation techniques to dis- tract him when flashbacks occur.
10
"OK. I am going that way myself."
11
Effexor and Ativan
12
Schizophrenia
13
Antiparkinsonian
14
Tardive dyskinesia
15
Traumatic event in childhood
16
Orthostatic hypotension
17
Offer nutritious finger foods and high-protein milk shakes to eat on the go.
18
Manic episode
19
Decrease the stimuli and use restraints if all other measures fail.
20
Maintain hydration.
21
Borderline
22
Obsessive-compulsive
23
Neoplasms
24
Diminished awareness of surroundings, Derealization, Depersonalization, Amnesia
25
A car backfiring being perceived as gunfire, The television news being perceived as someone talking to you, A spot on the wall being perceived as a spider
26
sensorium
27
1 month
28
Oxazepam (Serax)
29
Fluvoxamine (Luvox)
30
Patient reports sleeping better and increased in- terest in activities.
31
It requires medical intervention to treat.
32
Discuss, review, and validate the behavior moni- toring system and intervention flow sheet the patient and significant other will continue to use following
33
Risk of injury when using machinery
34
Patient with recent anxiety reactions
35
"You may feel dizzy or unsteady when rising to a standing position."
36
There is minimal potential for abuse.
37
provide for patient safety.
38
intramuscularly.
39
She is able to sleep 5 hours during the night., The tremor and pacing she exhibited on admission are reduced., She is able to attend and actively participate in group sessions.
40
Alcohol, Antihistamines, Analgesics, Sedatives, Hypnotics
41
Reduced need for sedation and analgesia before and after surgery, Control of itching in allergic reactions, Control of vomiting
42
Physical examination, Psychological evaluation, History of precipitation stressors, Medication history, Substance abuse history
43
readily cross into breast milk, enter fetal circulation
44
Distinct episodes of elation
45
Morphine
46
They do not cause the anticholinergic and cardio- vascular adverse effects.
47
Bipolar disorders
48
Social withdrawal
49
Patient age and gender
50
1 week
51
Blocking their destruction
52
Neck stiffness
53
Drowsiness
54
Bradycardia
55
"If I have the urge to smoke, I will take more med- ication."
56
Assess the patient for thoughts of suicide.
57
in 14 days following the last dose of
58
fluid volume deficit.
59
Current medications and medical history, Recent stressors and support system, Family history of mood disorder, Dietary patterns
60
"Persistent vomiting and profuse diarrhea are signs of toxicity and must be reported to the healthcare provider immediately.", "It is important to comply with schedules for blood tests to assess therapeutic levels.", The common adverse effects to expect, which are excessive nausea, anorexia, and abdominal cramps, tend to resolve.", "Take the medication with food or milk."
61
Dryness of the mouth is normal; sucking on sugar free hard candy and ice chips or chewing gum may help alleviate this problem., Rise slowly from a supine or sitting posi- tion to avoid dizziness and orthostatic hypotension., Avoid alcohol and barbiturates.
62
Beer, Aged cheeses, Bananas
63
Compliance with medication therapy within the last 2 months, Nonverbal interactions among patient and significant others present, Evaluation of the coherency, relevancy, and organization of thoughts in responses, Appearance and posture
64
SSRIs inhibit the destruction and reuptake of serotonin at the synaptic cleft., Monocyclic antidepressants such as bupropion (Wellbutrin) have an unknown mechanism of action., SNRIs prolong the action of neurotransmitters by decreasing the destruction of serotonin and norepinephrine.
65
Tranylcypromine (Parnate) Willihnganz, Lithium (Eskalith), Warfarin (Coumadin), Propranolol (Inderal)
66
Dryness of mouth, nose, and throat, Constipation, Urinary retention, Blurred vision
67
Hold the MAOI drug., Consult with the prescribing healthcare provider.
68
Hallucinations
69
Administration of depot antipsychotic medication
70
Extrapyramidal effects
71
Dystonic reactions
72
Agranulocytosis
73
Firmly redirect the patient to take the medication.
74
Painful dystonic reactions can occur in the first 72 hours of initiation of therapy.
75
Milligram doses used for the medication
76
Extrapyramidal symptoms
77
Measure the patient's waist circumference.
78
diphenhydramine
79
Deterioration of social functioning, Reporting that the FBI has solicited important secret information from his phone conversations, Confirmation of hearing voices in his head, Changing the topic of conversation inappropriately
80
Benzodiazepines allow for lower dosages of antipsychotic agents to be used, thereby decreasing serious adverse effects seen with high-dose therapy., It assists in calming the psy- chotic patient.
81
Spasmodic movements of muscle groups, Mask-like expression
82
Fever, Hypertension, Severe extrapyramidal symptoms, Alterations in consciousness
83
Be open and direct when handling the patient., Provide high-protein, high-calorie foods
84
Tardive dyskinesia, Neuroleptic malignant syndrome, Akathisia, Acute dystonia
85
Rapid increase in dosages will increase the frequency of adverse effects., Tardive dyskinesia may be re- versible in early stages, Full therapeutic response may require 6 to 8 weeks to be achieved.
86
Gingival hyperplasia
87
Hyperglycemia
88
Administer without mixing with other medications.
89
Trigeminal neuralgia pain
90
Valproic acid (Depakene)
91
Advise the patient that this adverse effect usually resolves but should be reported to the healthcare provider.
92
Topiramate (Topamax)
93
Nystagmus
94
Nystagmus
95
Nausea, vomiting, and indigestion are common during the initiation of therapy.
96
30 mg/min
97
"If I develop enlarged gums, I will stop taking the medication."
98
Determine patient's ancestry.
99
carbohydrates.
100
Placing padding around or under the patient's head, Positioning the patient on the side once the relaxation stage is entered to allow oral secretions to drain, Requesting additional assistance and/or necessary equipment in case the patient does not begin breathing spontaneously when the seizure is over